{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:29:13Z","timestamp":1793654953083,"version":"4.5.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Kay Yow Cancer Fund"},{"DOI":"10.13039\/100008615","name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008615","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s10549-021-06439-6","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T14:02:59Z","timestamp":1636120979000},"page":"409-422","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Patient-reported treatment toxicity and adverse events in Black and White women receiving chemotherapy for early breast cancer"],"prefix":"10.1007","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2974-480X","authenticated-orcid":false,"given":"K. A.","family":"Nyrop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. M.","family":"Damone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Deal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. B.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Charlot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. B.","family":"Reeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Basch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. S.","family":"Shachar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. A.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. E.","family":"Reeder-Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. C.","family":"Dees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. A.","family":"Jolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. G.","family":"Kimmick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. S.","family":"Karuturi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. E.","family":"Reinbolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"Speca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. B.","family":"Muss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,5]]},"reference":[{"issue":"1","key":"6439_CR1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3322\/caac.21320","volume":"66","author":"CE DeSantis","year":"2016","unstructured":"DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A (2016) Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin 66(1):31\u201342","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"6439_CR2","first-page":"438","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis CE, Ma J, Gaudet MM et al (2019) Breast cancer statistics, 2019. Cancer 69(6):438\u2013451","journal-title":"Cancer"},{"issue":"7","key":"6439_CR3","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1158\/1055-9965.EPI-15-0243","volume":"24","author":"L Tao","year":"2015","unstructured":"Tao L, Gomez SL, Keegan TH, Kurian AW, Clarke CA (2015) Breast cancer mortality in African-American and non-hispanic white women by molecular subtype and stage at diagnosis: a population-based study. Cancer Epidemiol Biomarkers Prev 24(7):1039\u20131045","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"21","key":"6439_CR4","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","volume":"295","author":"LA Carey","year":"2006","unstructured":"Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492\u20132502","journal-title":"JAMA"},{"issue":"1","key":"6439_CR5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2017.74.2049","volume":"36","author":"L Ellis","year":"2018","unstructured":"Ellis L, Canchola AJ, Spiegel D, Ladabaum U, Haile R, Gomez SL (2018) Racial and ethnic disparities in cancer survival: the contribution of tumor, sociodemographic, institutional, and neighborhood characteristics. J Clin Oncol 36(1):25\u201333","journal-title":"J Clin Oncol"},{"issue":"2","key":"6439_CR6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10549-018-4909-5","volume":"172","author":"AK Green","year":"2018","unstructured":"Green AK, Aviki EM, Matsoukas K, Patil S, Korenstein D, Blinder V (2018) Racial disparities in chemotherapy administration for early-stage breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 172(2):247\u2013263","journal-title":"Breast Cancer Res Treat"},{"issue":"17","key":"6439_CR7","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO.2017.77.6310","volume":"36","author":"SB Wheeler","year":"2018","unstructured":"Wheeler SB, Spencer JC, Pinheiro LC, Carey LA, Olshan AF, Reeder-Hayes KE (2018) Financial impact of breast cancer in black versus white women. J Clin Oncol 36(17):1695\u20131701","journal-title":"J Clin Oncol"},{"issue":"9","key":"6439_CR8","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1634\/theoncologist.2013-0243","volume":"18","author":"SB Wheeler","year":"2013","unstructured":"Wheeler SB, Reeder-Hayes KE, Carey LA (2013) Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research. Oncologist 18(9):986\u2013993","journal-title":"Oncologist"},{"issue":"20","key":"6439_CR9","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1200\/JCO.2014.57.1349","volume":"33","author":"ET Warner","year":"2015","unstructured":"Warner ET, Tamimi RM, Hughes ME et al (2015) Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors. J Clin Oncol 33(20):2254\u20132261","journal-title":"J Clin Oncol"},{"issue":"6","key":"6439_CR10","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/cncr.33288","volume":"127","author":"KA Nyrop","year":"2021","unstructured":"Nyrop KA, Deal A, Carey L et al (2021) Obesity, comorbidities and treatment selection in Black and White women with early breast cancer. Cancer 127(6):922\u2013930","journal-title":"Cancer"},{"issue":"2","key":"6439_CR11","first-page":"15","volume":"11","author":"CK Gwede","year":"2002","unstructured":"Gwede CK, Johnson DJ, Daniels SS, Trotti A (2002) Assessment of toxicity in cooperative oncology clinical trials: the long and short of it. J Oncol Manag. 11(2):15\u201321","journal-title":"J Oncol Manag."},{"key":"6439_CR12","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v.5. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 10\/23\/2017, 2017."},{"issue":"4","key":"6439_CR13","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.clinthera.2016.03.011","volume":"38","author":"E Basch","year":"2016","unstructured":"Basch E, Rogak LJ, Dueck AC (2016) Methods for implementing and reporting Patient-reported Outcome (PRO) measures of symptomatic adverse events in cancer clinical trials. Clin Ther 38(4):821\u2013830","journal-title":"Clin Ther"},{"issue":"8","key":"6439_CR14","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2016.6749","volume":"3","author":"E Basch","year":"2017","unstructured":"Basch E, Dueck AC, Rogak LJ et al (2017) Feasibility assessment of patient reporting of symptomatic adverse events in multicenter cancer clinical trials. JAMA Oncol 3(8):1043\u20131050","journal-title":"JAMA Oncol"},{"issue":"2","key":"6439_CR15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ijrobp.2017.02.002","volume":"98","author":"E Basch","year":"2017","unstructured":"Basch E, Pugh SL, Dueck AC et al (2017) Feasibility of patient reporting of symptomatic adverse events via the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in a chemoradiotherapy cooperative group multicenter clinical trial. Int J Radiat Oncol Biol Phys 98(2):409\u2013418","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"6439_CR16","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ygyno.2016.08.335","volume":"143","author":"RA Cowan","year":"2016","unstructured":"Cowan RA, Suidan RS, Andikyan V et al (2016) Electronic patient-reported outcomes from home in patients recovering from major gynecologic cancer surgery: a prospective study measuring symptoms and health-related quality of life. Gynecol Oncol 143(2):362\u2013366","journal-title":"Gynecol Oncol"},{"issue":"5","key":"6439_CR17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrclinonc.2015.222","volume":"13","author":"M Di Maio","year":"2016","unstructured":"Di Maio M, Basch E, Bryce J, Perrone F (2016) Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nat Rev Clin Oncol 13(5):319\u2013325","journal-title":"Nat Rev Clin Oncol"},{"key":"6439_CR18","unstructured":"National Cancer Institute. PRO-CTCAE TM version 1.0. 2018. Accessed 12\/17\/2018."},{"issue":"9","key":"6439_CR19","doi-asserted-by":"crossref","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","volume":"106","author":"E Basch","year":"2014","unstructured":"Basch E, Reeve BB, Mitchell SA et al (2014) Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 106(9):dju244","journal-title":"J Natl Cancer Inst."},{"issue":"8","key":"6439_CR20","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","volume":"1","author":"AC Dueck","year":"2015","unstructured":"Dueck AC, Mendoza TR, Mitchell SA et al (2015) Validity and reliability of the US National Cancer Institute\u2019s Patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol 1(8):1051\u20131059","journal-title":"JAMA Oncol"},{"issue":"7","key":"6439_CR21","doi-asserted-by":"crossref","first-page":"dju129","DOI":"10.1093\/jnci\/dju129","volume":"106","author":"BB Reeve","year":"2014","unstructured":"Reeve BB, Mitchell SA, Dueck AC et al (2014) Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. J Nat Cancer Inst 106(7):dju129","journal-title":"J Nat Cancer Inst"},{"key":"6439_CR22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12955-016-0426-6","volume":"14","author":"AV Bennett","year":"2016","unstructured":"Bennett AV, Dueck AC, Mitchell SA et al (2016) Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute\u2019s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Health Qual Life Outcomes 14:24","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"6439_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41687-017-0005-6","volume":"1","author":"C Baeksted","year":"2017","unstructured":"Baeksted C, Pappot H, Nissen A et al (2017) Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) in Danish prostate cancer patients. J Patient Rep Outcomes 1(1):1\u201311","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"6439_CR24","first-page":"1169","volume":"3","author":"A Stover","year":"2015","unstructured":"Stover A, Irwin DE, Chen RC et al (2015) Integrating patient-reported outcome measures into routine cancer care: cancer patients\u2019 and clinicians\u2019 perceptions of acceptability and value. EGEMS (Washington, DC) 3(1):1169","journal-title":"EGEMS (Washington, DC)"},{"issue":"6","key":"6439_CR25","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1634\/theoncologist.2018-0590","volume":"24","author":"KA Nyrop","year":"2019","unstructured":"Nyrop KA, Deal AM, Shachar SS et al (2019) Patient-reported toxicities during chemotherapy regimens in current clinical practice for early breast cancer. Oncologist 24(6):762\u2013771","journal-title":"Oncologist"},{"issue":"3","key":"6439_CR26","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.jpainsymman.2017.10.024","volume":"55","author":"TM Atkinson","year":"2018","unstructured":"Atkinson TM, Hay JL, Dueck AC et al (2018) What do \u201cNone,\u201d \u201cMild,\u201d \u201cModerate,\u201d \u201cSevere,\u201d and \u201cVery Severe\u201d mean to patients with cancer? Content validity of PRO-CTCAE response scales. J Pain Symptom Manage 55(3):e3\u2013e6","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"6439_CR27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.6004\/jnccn.2018.0012","volume":"16","author":"WJ Gradishar","year":"2018","unstructured":"Gradishar WJ, Anderson BO, Balassanian R et al (2018) Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 16(3):310\u2013320","journal-title":"J Natl Compr Canc Netw"},{"issue":"13","key":"6439_CR28","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1002\/cncr.32898","volume":"126","author":"KA Nyrop","year":"2020","unstructured":"Nyrop KA, Deal AM, Reeve BB (2020) Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer. Cancer 126(13):3084\u20133093","journal-title":"Cancer"},{"issue":"7","key":"6439_CR29","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1002\/cncr.32175","volume":"127","author":"KA Nyrop","year":"2019","unstructured":"Nyrop KA, Deal AM, Reeder-Hayes KE et al (2019) Patient and clinician-reported chemotherapy-induced peripheral neuropathy (CIPN) in early breast cancer: current clinical practice. Cancer 127(7):2945\u20132954","journal-title":"Cancer"},{"issue":"2","key":"6439_CR30","doi-asserted-by":"crossref","first-page":"M85","DOI":"10.1093\/geronj\/49.2.M85","volume":"49","author":"L Guralnik","year":"1994","unstructured":"Guralnik L, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF et al (1994) A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol Med Sci 49(2):M85\u2013M94","journal-title":"J Gerontol Med Sci"},{"issue":"80","key":"6439_CR31","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/ptj\/80.9.896","volume":"2000","author":"A Shumway-Cook","year":"2000","unstructured":"Shumway-Cook A, Brauer S, Woollacott M (2000) Predicting the probability of falls in community-dwelling older adults using the timed up and go test. Phys Ther 2000(80):896\u2013903","journal-title":"Phys Ther"},{"issue":"39","key":"6439_CR32","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","volume":"1991","author":"D Podsiadlo","year":"1991","unstructured":"Podsiadlo D, Richardson S (1991) The timed \u201cUp & Go\u201d: a test of functional mobility for frail elderly persons. J Am Geriatr Soc 1991(39):142\u2013148","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"6439_CR33","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/089198879500800408","volume":"8","author":"C Kawas","year":"1995","unstructured":"Kawas C, Karagiozis H, Resau L, Corrada M, Brookmeyer R (1995) Reliability of the blessed telephone information-memory-concentration test. J Geriatr Psychiatry Neurol 8(4):238\u2013242","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"6","key":"6439_CR34","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1176\/ajp.140.6.734","volume":"140","author":"R Katzman","year":"1983","unstructured":"Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H (1983) Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry 140(6):734\u2013739","journal-title":"Am J Psychiatry"},{"issue":"4","key":"6439_CR35","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/geronj\/36.4.428","volume":"36","author":"GG Fillenbaum","year":"1981","unstructured":"Fillenbaum GG, Smyer MA (1981) The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. J Gerontol 36(4):428\u2013434","journal-title":"J Gerontol"},{"issue":"2","key":"6439_CR36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jgo.2018.08.009","volume":"10","author":"M Pergolotti","year":"2019","unstructured":"Pergolotti M, Langer MM, Deal AM, Muss HB, Nyrop K, Williams G (2019) Mental status evaluation in older adults with cancer: development of the Mental Health Index-13. J Geriatr Oncol 10(2):241\u2013245","journal-title":"J Geriatr Oncol"},{"key":"6439_CR37","volume-title":"Measuring Functioning and Well-being: the Medical Outcome Study Approach","author":"A Stewart","year":"1992","unstructured":"Stewart A, Ware JE (1992) Measuring Functioning and Well-being: the Medical Outcome Study Approach. Duke University Press, Durham NC"},{"key":"6439_CR38","first-page":"173","volume-title":"Measuring Functioning and Well-being: The Medical Outcomes Study","author":"CD Sherbourne","year":"1991","unstructured":"Sherbourne CD (1991) Social Functioning: Social Activity Limitations Measure. In: Stewart AL, Ware JE (eds) Measuring Functioning and Well-being: The Medical Outcomes Study. Duke University Press, Durham and London, pp 173\u2013181"},{"issue":"6","key":"6439_CR39","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/0277-9536(91)90150-B","volume":"32","author":"CD Sherbourne","year":"1991","unstructured":"Sherbourne CD, Stewart AL (1991) The MOS social support survey. Soc Sci Med 32(6):705\u2013714","journal-title":"Soc Sci Med"},{"issue":"3","key":"6439_CR40","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570\u2013579","journal-title":"J Clin Oncol"},{"key":"6439_CR41","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","volume":"1","author":"K Webster","year":"2003","unstructured":"Webster K, Cella D, Yost K (2003) The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 1:79","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"6439_CR42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11136-013-0470-1","volume":"23","author":"JL Hay","year":"2014","unstructured":"Hay JL, Atkinson TM, Reeve BB et al (2014) Cognitive interviewing of the US National Cancer Institute\u2019s Patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Qual Life Res 23(1):257\u2013269","journal-title":"Qual Life Res"},{"issue":"4","key":"6439_CR43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/aje\/kwh221","volume":"160","author":"S Greenland","year":"2004","unstructured":"Greenland S (2004) Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies. Am J Epidemiol 160(4):301\u2013305","journal-title":"Am J Epidemiol"},{"issue":"7","key":"6439_CR44","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/aje\/kwh090","volume":"159","author":"G Zou","year":"2004","unstructured":"Zou G (2004) A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 159(7):702\u2013706","journal-title":"Am J Epidemiol"},{"issue":"2","key":"6439_CR45","doi-asserted-by":"crossref","first-page":"118","DOI":"10.6004\/jnccn.2019.0009","volume":"17","author":"MP Goetz","year":"2019","unstructured":"Goetz MP, Gradishar WJ, Anderson BO et al (2019) NCCN guidelines insights: breast cancer, version 3.2018. J Natl Compr Canc Netw 17(2):118\u2013126","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"6439_CR46","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00520-011-1089-9","volume":"19","author":"SH Ridner","year":"2011","unstructured":"Ridner SH, Dietrich MS, Stewart BR, Armer JM (2011) Body mass index and breast cancer treatment-related lymphedema. Support Care Cancer 19(6):853\u2013857","journal-title":"Support Care Cancer"},{"issue":"53","key":"6439_CR47","first-page":"2002","volume":"1983","author":"V Mor","year":"1983","unstructured":"Mor V, Laliberte L, Morris JN, Wiemann M (1983) The Karnofsky performance status scale: an examination of its reliability and validity in a research setting. Cancer 1983(53):2002\u20132007","journal-title":"Cancer"},{"key":"6439_CR48","doi-asserted-by":"crossref","first-page":"109312","DOI":"10.1016\/j.mehy.2019.109312","volume":"131","author":"JMP de Godoy","year":"2019","unstructured":"de Godoy JMP (2019) Systemic subclinical lymphedema due to obesity as the cause of clinical lymphedema: a new concept. Med Hypotheses 131:109312","journal-title":"Med Hypotheses"},{"key":"6439_CR49","doi-asserted-by":"publisher","DOI":"10.1089\/wound.2020.1337","author":"CL Sudduth","year":"2021","unstructured":"Sudduth CL, Greene AK (2021) Current overview of obesity-induced lymphedema. Adv Wound Care. https:\/\/doi.org\/10.1089\/wound.2020.1337","journal-title":"Adv Wound Care"},{"issue":"2","key":"6439_CR50","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/lrb.2013.0004","volume":"11","author":"S Ugur","year":"2013","unstructured":"Ugur S, Ar\u0131c\u0131 C, Yaprak M et al (2013) Risk factors of breast cancer-related lymphedema. Lymphat Res Biol 11(2):72\u201375","journal-title":"Lymphat Res Biol"},{"key":"6439_CR51","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/2193-1801-3-366","volume":"3","author":"B Bhatnagar","year":"2014","unstructured":"Bhatnagar B, Gilmore S, Goloubeva O et al (2014) Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. Springerplus 3:366","journal-title":"Springerplus"},{"issue":"1","key":"6439_CR52","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/A:1025481505537","volume":"81","author":"JJ Griggs","year":"2003","unstructured":"Griggs JJ, Sorbero ME, Stark AT, Heininger SE, Dick AW (2003) Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy. Breast Cancer Res Treat 81(1):21\u201331","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"6439_CR53","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/NCC.0000000000000139","volume":"38","author":"JS Wells","year":"2015","unstructured":"Wells JS, Strickland OL, Dalton JA, Freeman S (2015) Adherence to intravenous chemotherapy in African American and white women with early-stage breast cancer. Cancer Nurs 38(2):89\u201398","journal-title":"Cancer Nurs"},{"issue":"1","key":"6439_CR54","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10549-016-3855-3","volume":"158","author":"AI Neugut","year":"2016","unstructured":"Neugut AI, Hillyer GC, Kushi LH et al (2016) A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL). Breast Cancer Res Treat 158(1):127\u2013138","journal-title":"Breast Cancer Res Treat"},{"key":"6439_CR55","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-010713-141500","volume":"65","author":"E Basch","year":"2014","unstructured":"Basch E (2014) New frontiers in patient-reported outcomes: adverse event reporting, comparative effectiveness, and quality assessment. Annu Rev Med 65:307\u2013317","journal-title":"Annu Rev Med"},{"issue":"10","key":"6439_CR56","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JOP.2016.015610","volume":"12","author":"AM Stover","year":"2016","unstructured":"Stover AM, Basch EM (2016) Implementation of symptom questionnaires into oncology workflow. J Oncol Pract 12(10):859\u2013862","journal-title":"J Oncol Pract"},{"key":"6439_CR57","doi-asserted-by":"crossref","first-page":"139","DOI":"10.14694\/EdBook_AM.2012.32.80","volume":"32","author":"DW Bruner","year":"2012","unstructured":"Bruner DW, Movsas B, Basch E (2012) Capturing the patient perspective: patient-reported outcomes as clinical trial endpoints. Am Soc Clin Oncol Educ Book 32:139\u2013144","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"6439_CR58","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jamaoncol.2015.4719","volume":"2","author":"E Basch","year":"2016","unstructured":"Basch E (2016) Missing patients\u2019 symptoms in cancer care delivery-the importance of patient-reported outcomes. JAMA Oncol 2(4):433\u2013434","journal-title":"JAMA Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06439-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06439-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06439-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T15:35:36Z","timestamp":1642433736000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06439-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,5]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["6439"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06439-6","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,5]]},"assertion":[{"value":"8 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was received from all study participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}